Literature DB >> 14557591

Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.

I Rojas-Marcos1, D Calvet, P Janoray, J Y Delattre.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557591     DOI: 10.1212/01.wnl.0000082384.15848.fa

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Targets for therapy in ependymoma.

Authors:  Nicole A Shonka
Journal:  Target Oncol       Date:  2011-03-29       Impact factor: 4.493

Review 2.  Ependymomas in adults.

Authors:  Mark R Gilbert; Roberta Ruda; Riccardo Soffietti
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

3.  Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.

Authors:  Andrew M Donson; Vladimir Amani; Elliot A Warner; Andrea M Griesinger; Davis A Witt; Jean M Mulcahy Levy; Lindsey M Hoffman; Todd C Hankinson; Michael H Handler; Rajeev Vibhakar; Kathleen Dorris; Nicholas K Foreman
Journal:  Mol Cancer Ther       Date:  2018-06-20       Impact factor: 6.261

Review 4.  EANO guidelines for the diagnosis and treatment of ependymal tumors.

Authors:  Roberta Rudà; Guido Reifenberger; Didier Frappaz; Stefan M Pfister; Anne Laprie; Thomas Santarius; Patrick Roth; Joerg Christian Tonn; Riccardo Soffietti; Michael Weller; Elizabeth Cohen-Jonathan Moyal
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

5.  Current treatment options for pediatric and adult patients with ependymoma.

Authors:  Karen D Wright; Amar Gajjar
Journal:  Curr Treat Options Oncol       Date:  2012-12

6.  Chemotherapy for intracranial ependymoma in adults.

Authors:  Dorothee Gramatzki; Patrick Roth; Jörg Felsberg; Silvia Hofer; Elisabeth J Rushing; Bettina Hentschel; Manfred Westphal; Dietmar Krex; Matthias Simon; Oliver Schnell; Wolfgang Wick; Guido Reifenberger; Michael Weller
Journal:  BMC Cancer       Date:  2016-04-23       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.